Clinical Trial Update: A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a dendritic cell/multiple myeloma fusion vaccine in combination with elranatamab for relapsed or refractory multiple myeloma; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Dendritic cell/multiple myeloma fusion vaccine
• Elranatamab (elranatamab)

Snippet

Sponsor: David Avigan | Conditions: Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Status: RECRUITING